Illumina Q1 revenue down 11% YoY to $1.09B; GAAP EPS $0.02 vs $0.55; reiterates FY23 guidance

ILLUMINA, INC.

2023-Q1 EPS reported $0.02 revenue$1,087,000,000

Revenue $1.087B, down 11% YoY (down 9% constant currency); GAAP diluted EPS $0.02 vs $0.55.
Non-GAAP diluted EPS $0.08 vs $1.07; non-GAAP operating margin 1.9% vs 17.3%.
Reiterated FY2023 revenue growth 7-10% and non-GAAP EPS $1.25-$1.50; GAAP loss per share $(0.28)-$(0.03).
Committed to Core Illumina non-GAAP operating margins of 25% in FY2024 and 27% in FY2025.
Shipped 67 NovaSeq X instruments in Q1 (exceeded plan); order book >200; plan >$100M annual cost savings.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ILLUMINA, INC. reported the first quarter ended April 2, 2023 results: revenue $1.09 billion, net income $3, EPS $0.02. Guidance reaffirmed.

Period: the first quarter ended April 2, 2023
Revenue: $1.09 billion
Net income: $3
EPS: $0.02
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Illumina Reports Financial Results for First Quarter of Fiscal Year 2023; Announces Commitment to Accelerate Margin Growth • Revenue of $1.09 billion for Q1 2023, up 1% from Q4 2022; down 11% from Q1 2022 (down 9% on a constant currency basis) • GAAP diluted EPS of $0.02 for Q1 2023, compared to GAAP diluted EPS of $0.55 for Q1 2022 • Non-GAAP diluted EPS of $0.08 for Q1 2023, compared to non-GAAP diluted EPS of $1.07 for Q1 2022

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

ILLUMINA, INC. filing history →

Source: SEC EDGAR

accession 0001110803-23-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.